These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 22954905

  • 1. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
    San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.
    Psychiatry Res; 2012 Dec 30; 200(2-3):693-701. PubMed ID: 22954905
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
    Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA.
    BMC Psychiatry; 2010 Mar 24; 10():26. PubMed ID: 20334680
    [Abstract] [Full Text] [Related]

  • 3. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
    Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B.
    Int J Neuropsychopharmacol; 2020 Apr 23; 23(4):217-229. PubMed ID: 31974576
    [Abstract] [Full Text] [Related]

  • 4. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.
    Johnsen E, Jørgensen HA, Kroken RA, Løberg EM.
    Eur Psychiatry; 2013 Mar 23; 28(3):174-84. PubMed ID: 22153730
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2006 Apr 23; 163(4):611-22. PubMed ID: 16585435
    [Abstract] [Full Text] [Related]

  • 6. Ziprasidone versus other atypical antipsychotics for schizophrenia.
    Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD006627. PubMed ID: 19821380
    [Abstract] [Full Text] [Related]

  • 7. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.
    World J Biol Psychiatry; 2009 Oct 07; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [Abstract] [Full Text] [Related]

  • 8. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
    Johnsen E, Sinkeviciute I, Løberg EM, Kroken RA, Hugdahl K, Jørgensen HA.
    BMC Psychiatry; 2013 Sep 30; 13():241. PubMed ID: 24079855
    [Abstract] [Full Text] [Related]

  • 9. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.
    J Med Assoc Thai; 2005 Sep 30; 88(9):1267-77. PubMed ID: 16536115
    [Abstract] [Full Text] [Related]

  • 10. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.
    Kjelby E, Jørgensen HA, Kroken RA, Løberg EM, Johnsen E.
    BMC Psychiatry; 2011 Aug 31; 11():145. PubMed ID: 21884578
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST study group.
    Lancet; 2008 Mar 29; 371(9618):1085-97. PubMed ID: 18374841
    [Abstract] [Full Text] [Related]

  • 12. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y, Kim E, You M, Pikalov A, Tran QV.
    J Med Econ; 2009 Jun 29; 12(2):104-13. PubMed ID: 19527195
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
    N Engl J Med; 2005 Sep 22; 353(12):1209-23. PubMed ID: 16172203
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
    Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S.
    Schizophr Bull; 2012 Jun 22; 38(4):845-53. PubMed ID: 21307041
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW, EUFEST Study Group.
    J Clin Psychiatry; 2011 Jul 22; 72(7):955-61. PubMed ID: 21824456
    [Abstract] [Full Text] [Related]

  • 16. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.
    J Clin Psychiatry; 2008 Dec 22; 69(12):1901-15. PubMed ID: 19012820
    [Abstract] [Full Text] [Related]

  • 17. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.
    J Am Pharm Assoc (2003); 2007 Dec 22; 47(3):373-8. PubMed ID: 17510032
    [Abstract] [Full Text] [Related]

  • 18. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ, Liu-Seifert H, Adams DH, Citrome L.
    J Clin Psychopharmacol; 2006 Dec 22; 26(6):632-7. PubMed ID: 17110821
    [Abstract] [Full Text] [Related]

  • 19. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Zedkova I, Dudova I, Urbanek T, Hrdlicka M.
    Neuro Endocrinol Lett; 2011 Dec 22; 32(5):667-70. PubMed ID: 22167144
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD.
    Am J Psychiatry; 2007 Jul 22; 164(7):1050-60. PubMed ID: 17606657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.